

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/379537002>

Oxidative Stress and Redox Signaling in the Pathophysiology of Sickle Cell Disease: A Review

Article in *Haematology International Journal* · April 2024

DOI: 10.23880/hij-16000247

CITATIONS

0

READS

22

2 authors:



Emmanuel Ifeanyi Obeagu
Kampala International University (KIU)

1,601 PUBLICATIONS 20,695 CITATIONS

SEE PROFILE



Getrude Uzoma Obeagu
Kampala International University (KIU)

515 PUBLICATIONS 9,302 CITATIONS

SEE PROFILE



Oxidative Stress and Redox Signaling in the Pathophysiology of Sickle Cell Disease: A Review

Emmanuel Ifeanyi Obeagu^{1*} and Getrude Uzoma Obeagu²

¹Department of Medical Laboratory Science, Kampala International University, Uganda

²School of Nursing Science, Kampala International University, Uganda

***Corresponding author:** Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Kampala, Uganda, Tel: +2348037369912; Email: emmanuelobeagu@yahoo.com; obeagu.emmanuel@kiu.ac.ug

Review Article

Volume 8 Issue 1

Received Date: March 13, 2024

Published Date: April 03, 2024

DOI: 10.23880/hij-16000247

Abstract

Sickle Cell Disease (SCD) is a hereditary hemoglobinopathy characterized by the aberrant hemoglobin S, resulting in the formation of sickle-shaped red blood cells and a cascade of clinical complications. While the molecular aspects of SCD are well-elucidated, recent investigations underscore the critical influence of oxidative stress and redox signaling in the disease's pathophysiology. This comprehensive review synthesizes current knowledge on the interplay between oxidative stress, redox signaling, and SCD, providing insights into potential therapeutic targets. Discussions encompass the generation of reactive oxygen species (ROS), antioxidant defense mechanisms, and the activation of redox-sensitive signaling pathways. The consequences of oxidative stress, such as vaso-occlusion, inflammation, and endothelial dysfunction, are examined in detail. Furthermore, the review evaluates existing antioxidant therapies, explores potential strategies targeting redox signaling pathways, and discusses emerging therapeutic targets. By elucidating the intricate relationship between oxidative stress and SCD, this review aims to advance our understanding of the disease's complexity and pave the way for innovative therapeutic interventions, offering renewed hope for enhanced patient care and management.

Keywords: Sickle Cell Disease; Oxidative Stress; Redox Signaling; Reactive Oxygen Species; Antioxidants; Inflammation; Vaso-Occlusion

Abbreviations: ROS: Reactive Oxygen Species; SCD: Sickle Cell Disease; HbS: hemoglobins; Nrf2: Nuclear factor erythroid 2-related factor; ARE: Antioxidant Response Elements.

Introduction

Sickle Cell Disease (SCD) is a genetic disorder characterized by the presence of abnormal hemoglobin,

known as hemoglobinS (HbS) [1]. This condition leads to the formation of sickle-shaped red blood cells, causing various complications such as vaso-occlusion, hemolysis, and impaired blood flow. One emerging area of research in understanding the pathophysiology of SCD is the role of oxidative stress and redox signaling. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the ability of antioxidant defense systems to neutralize them. This imbalance can result

in cellular damage, inflammation, and alterations in cellular signaling pathways [2]. The redox signaling pathways, which involve the transfer of electrons between molecules, play a crucial role in regulating cellular processes [2]. In SCD, the abnormal hemoglobin S undergoes polymerization, leading to increased susceptibility to oxidative stress [4]. The high levels of ROS produced during this process contribute to oxidative damage in various cellular components, including lipids, proteins, and DNA [5]. The intricate relationship between oxidative stress and redox signaling in the context of SCD has garnered significant attention in recent years.

This review aims to explore the current understanding of oxidative stress and redox signaling in the pathophysiology of SCD. It will delve into the molecular mechanisms underlying the production of ROS in SCD and the impact of oxidative stress on different cellular compartments. Additionally, the review will address the role of redox signaling in modulating cellular responses to oxidative stress in SCD. Understanding these intricate mechanisms is crucial for developing targeted therapeutic strategies that can mitigate the effects of oxidative stress and redox imbalance in individuals with SCD.

Aim

The aim of this review article is to comprehensively examine the role of oxidative stress and redox signaling in the pathophysiology of Sickle Cell Disease (SCD). The review will delve into the molecular mechanisms underlying the generation of reactive oxygen species (ROS), the consequences of oxidative stress on cellular components, and the intricate interplay with redox signaling pathways.

Oxidative Stress in Sickle Cell Disease

Oxidative stress in Sickle Cell Disease (SCD) represents a critical facet of the underlying pathophysiology, contributing significantly to the disease's complications and progression. The primary instigator is the abnormal hemoglobin, HbS, which undergoes polymerization, triggering a cascade of events leading to increased production of reactive oxygen species (ROS). The red blood cells in individuals with SCD are particularly susceptible to oxidative stress due to the hemoglobin S polymerization process, resulting in the formation of sickle-shaped cells that are more prone to oxidative damage [6,7]. The imbalance between ROS production and the antioxidant defense mechanisms creates a state of oxidative stress [8]. This heightened oxidative stress in SCD results in the peroxidation of lipids, oxidation of proteins, and damage to nucleic acids, collectively impacting various cellular components. This damage, in turn, exacerbates inflammation and disrupts cellular signaling pathways, amplifying the overall pathology of SCD [9].

One major consequence of oxidative stress in SCD is the increased fragility of red blood cells, leading to hemolysis and the release of free hemoglobin into the bloodstream. This liberated hemoglobin contributes further to oxidative stress by generating additional ROS. The cumulative effects of oxidative stress in SCD extend beyond the red blood cells, affecting endothelial cells, leukocytes, and other cell types, thereby perpetuating a systemic state of oxidative imbalance [10]. Moreover, oxidative stress in SCD has been linked to endothelial dysfunction, contributing to vaso-occlusion, impaired blood flow, and tissue damage. Endothelial cells, when exposed to high levels of ROS, exhibit altered vasoregulation and increased adhesion molecule expression, fostering a pro-inflammatory and pro-thrombotic microenvironment [11]. This endothelial dysfunction plays a pivotal role in the vascular complications associated with SCD, including acute chest syndrome and stroke.

Redox Signaling Pathways in Sickle Cell Disease

Redox signaling pathways play a pivotal role in the intricate pathophysiology of Sickle Cell Disease (SCD) [12]. The aberrant hemoglobin S (HbS) in individuals with SCD undergoes polymerization, contributing to increased oxidative stress. This heightened oxidative state is closely linked to the dysregulation of redox signaling, influencing various cellular processes and exacerbating the complications associated with the disease.

One key aspect of redox signaling in SCD is its impact on cellular adhesion. Oxidative stress induces the upregulation of adhesion molecules on endothelial cells, red blood cells, and leukocytes. This heightened expression fosters increased cell adhesion, contributing to the formation of microvascular occlusions characteristic of SCD. Redox-sensitive transcription factors, such as nuclear factor-kappa B (NF- κ B), are implicated in this process, orchestrating the expression of adhesion molecules and driving the inflammatory response [13]. Redox signaling pathways also influence the delicate balance between nitric oxide (NO) and reactive oxygen species (ROS) in SCD [14]. NO, a crucial vasodilator, is inactivated by excess ROS, leading to endothelial dysfunction and impaired blood vessel regulation. This dysregulation in the NO/ROS balance contributes to vaso-occlusive events, promoting the formation of sickled cells and further impeding blood flow.

Mitochondria, vital cellular organelles, are also impacted by redox signaling in SCD [15]. Oxidative stress influences mitochondrial dysfunction, triggering a cascade of events leading to increased ROS production within these organelles. This mitochondrial dysfunction contributes to the overall oxidative burden in SCD, exacerbating cellular damage and influencing cellular signaling pathways involved in

apoptosis and inflammation. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway is another redox-sensitive pathway implicated in SCD [16]. Nrf2 is a master regulator of antioxidant response elements (AREs), and its activation is crucial for cellular defense against oxidative stress. In SCD, the dysregulated Nrf2 pathway may compromise the antioxidant defenses, contributing to the overwhelming oxidative environment. Targeting redox-sensitive pathways presents an avenue for developing novel treatments that could mitigate the impact of oxidative stress on disease progression. Antioxidant therapies, including small molecules and natural compounds, are being explored for their potential to restore redox balance and alleviate SCD complications.

Consequences of Oxidative Stress and Redox Imbalance

The consequences of oxidative stress and redox imbalance are wide-ranging, affecting numerous cellular components and processes. When the delicate equilibrium between reactive oxygen species (ROS) production and antioxidant defenses is disrupted, various adverse outcomes ensue, impacting cellular function, tissue integrity, and overall physiological homeostasis [17]. One prominent consequence is oxidative damage to biomolecules, including lipids, proteins, and nucleic acids. Lipid peroxidation, a result of ROS attacking cell membranes, compromises membrane integrity and fluidity, leading to cellular dysfunction [18]. Protein oxidation can alter the structure and function of essential proteins, impairing enzymatic activities and disrupting cellular signaling pathways. Nucleic acid damage, particularly to DNA, may result in mutations, genomic instability, and compromised cellular viability. Cellular signaling pathways are significantly affected by oxidative stress and redox imbalance. Redox-sensitive transcription factors, such as nuclear factor-kappa B (NF- κ B) and activator protein-1 (AP-1), are activated in response to oxidative stress, leading to the upregulation of pro-inflammatory and pro-survival genes [19]. This dysregulation contributes to chronic inflammation, a hallmark of many diseases, including neurodegenerative disorders, cardiovascular diseases, and cancers.

Mitochondrial dysfunction is another critical consequence of oxidative stress. Mitochondria, being a major source and target of ROS, are particularly vulnerable to oxidative damage [20]. Impaired mitochondrial function leads to a diminished capacity for energy production, disrupted cellular respiration, and an increased propensity for apoptotic cell death. This cascade of events further exacerbates the overall oxidative burden and contributes to the pathogenesis of various diseases. Oxidative stress and redox imbalance play a significant role in the progression

of chronic diseases, including neurodegenerative disorders such as Alzheimer's and Parkinson's diseases [21]. In these conditions, the cumulative effects of oxidative damage contribute to neuronal cell death, synaptic dysfunction, and the formation of pathological protein aggregates. Additionally, oxidative stress has been implicated in cardiovascular diseases, contributing to endothelial dysfunction, atherosclerosis, and myocardial infarction. The oxidation of low-density lipoproteins (LDL) and the activation of redox-sensitive signaling pathways in vascular cells contribute to the pro-atherogenic environment [22]. The consequences of oxidative stress extend beyond cellular and molecular levels, impacting overall tissue and organ function. Oxidative stress has been linked to accelerated aging, as it promotes cellular senescence and the accumulation of damage over time [23]. Moreover, it plays a role in the development and progression of cancer by promoting genomic instability and supporting the survival and proliferation of malignant cells.

Therapeutic Approaches and Future Perspectives

Therapeutic approaches targeting oxidative stress and redox imbalance have gained significant attention due to their potential in mitigating the detrimental effects associated with a wide array of diseases [24]. These strategies aim to restore redox homeostasis, enhance antioxidant defenses, and modulate redox-sensitive signaling pathways. While current interventions vary, the multifaceted nature of oxidative stress demands a comprehensive and personalized approach for optimal therapeutic outcomes. Antioxidant compounds, such as vitamins C and E, glutathione, and coenzyme Q10, have been investigated for their potential in neutralizing excess ROS and reducing oxidative damage [25]. However, the effectiveness of antioxidant supplementation may vary depending on the specific disease context, and achieving the right balance is crucial, as excessive antioxidant intake may also have adverse effects. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway is a key regulator of cellular antioxidant responses [26]. Therapeutic strategies that activate Nrf2 and enhance the expression of antioxidant enzymes show promise in mitigating oxidative stress. Small molecules and natural compounds, such as sulforaphane from broccoli, are being explored for their ability to activate the Nrf2 pathway.

Targeting mitochondrial dysfunction is a critical aspect of therapeutic approaches against oxidative stress. Compounds that enhance mitochondrial biogenesis, improve mitochondrial membrane potential, and reduce ROS production within mitochondria may offer potential benefits [27-30]. Coenzyme Q10, idebenone, and mitochondrial-targeted antioxidants fall into this category. Several drugs have been repurposed or designed to modulate redox

signaling pathways. For instance, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) exhibit redox-modulating properties and have been explored for their potential benefits in conditions such as cardiovascular diseases and diabetic complications. Emerging therapeutic strategies involve gene therapies aimed at enhancing the expression of antioxidant enzymes or modulating redox-sensitive transcription factors. These approaches offer the potential for long-term correction of redox imbalances but are still in the early stages of development. Adopting a healthy lifestyle, including regular exercise, a balanced diet rich in antioxidants, and stress management, represents a crucial aspect of preventing and managing oxidative stress. Lifestyle interventions can complement pharmacological approaches, providing a holistic strategy for maintaining redox homeostasis [31-63].

Future Perspectives

The future of therapeutic approaches against oxidative stress holds exciting possibilities. Advances in understanding redox signaling pathways and the development of more targeted interventions are likely to refine current strategies. Additionally, personalized medicine approaches, considering individual variations in redox status and response to therapies, may enhance treatment efficacy. Innovations in nanotechnology also offer novel delivery mechanisms for antioxidants and redox-modulating compounds, improving bioavailability and targeting specific cellular compartments. Furthermore, ongoing research into the identification of specific redox biomarkers may enable early detection of oxidative stress-related diseases and facilitate more precise therapeutic interventions [57].

Conclusion

The exploration of oxidative stress and redox signaling in the context of Sickle Cell Disease (SCD) provides a comprehensive understanding of the molecular intricacies underlying this complex genetic disorder. The aberrant hemoglobin S (HbS) polymerization in SCD leads to heightened oxidative stress, disrupting the delicate balance between reactive oxygen species (ROS) production and antioxidant defenses. The consequences of this redox imbalance are far-reaching, impacting cellular components, signaling pathways, and contributing to the disease's clinical manifestations. The consequences of oxidative stress in SCD include the oxidative damage of lipids, proteins, and nucleic acids, which further perpetuates inflammation and disrupts cellular function. Redox-sensitive pathways, such as those involving NF- κ B and Nrf2, play pivotal roles in the modulation of cellular responses to oxidative stress. Additionally, oxidative stress in SCD contributes to endothelial dysfunction, vaso-

occlusive events, and various complications, emphasizing its significance in disease progression.

Therapeutically, targeting oxidative stress and redox imbalance in SCD holds promise for mitigating the impact of this genetic disorder. Strategies involving antioxidant supplementation, Nrf2 activation, mitochondrial protection, and redox-modulating drugs are being explored for their potential in restoring redox homeostasis. Lifestyle interventions and the development of gene therapies further expand the therapeutic landscape, offering a holistic approach to managing oxidative stress-related complications.

References

1. Aleluia MM, Fonseca TC, Souza RQ, Neves FI, Santiago RP, et al. (2017) Comparative Study of Sickle Cell Anemia and Hemoglobin SC Disease: Clinical Characterization, Laboratory Biomarkers and Genetic Profiles. *BMC Hematol* 17(15): 1-10.
2. Bhattacharya S (2015) Reactive Oxygen Species and Cellular Defense System. *Free Radicals in Human Health and Disease* pp: 17-29.
3. Hubner C, Haase H (2021) Interactions of Zinc-and Redox-signaling Pathways. *Redox Biol* 41: 101916.
4. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, et al. (2021) Sickle Cell Disease: Role of Oxidative Stress and Antioxidant Therapy. *Antioxidants* 10(2): 296.
5. Juan CA, Perez de la Lastra JM, Plou FJ, Perez-Lebena E (2021) The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies. *Int J Mol Sci* 22(9): 4642.
6. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB (2023) Antioxidants in the Management of Sickle Cell Anaemia: An Area to be Exploited for the Wellbeing of the Patients. *International Research in Medical and Health Sciences* 6(4): 12-17.
7. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH (2024) Understanding Apoptosis in Sickle Cell Anemia Patients: Mechanisms and Implications. *Medicine* 103(2): e36898.
8. Sharma P, Jha AB, Dubey RS, Pessaraki M (2012) Reactive Oxygen Species, Oxidative Damage, and Antioxidative Defense Mechanism in Plants under Stressful Conditions. *Journal of Botany* 2012: 217037.
9. Shah F, Dwivedi M (2020) Pathophysiology and Recent Therapeutic Insights of Sickle Cell Disease. *Annals of*

- Hematology 99: 925-935.
10. Wang Q, Zennadi R (2021) The Role of RBC Oxidative Stress in Sickle Cell Disease: from the Molecular basis to Pathologic Implications. *Antioxidants* 10(10): 1608.
 11. Stierschneider A, Wiesner C (2023) Shedding Light on the Molecular and Regulatory Mechanisms of TLR4 Signaling in Endothelial Cells under Physiological and Inflamed Conditions. *Front Immunol* 14: 1264889.
 12. Alramadhani D, Aljahdali AS, Abdulmalik O, Pierce BD, Safo MK (2022) Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities. *Int J Mol Sci* 23(13): 7448.
 13. Rossignol SL, Ketheesan N, Haleagrahara N (2018) Redox-sensitive Transcription Factors Play a Significant Role in the Development of Rheumatoid Arthritis. *Int Rev Immunol* 37(3): 129-143.
 14. Akhter MS, Hamali HA, Rashid H, Dobie G, Madkhali AM, et al. (2023) Mitochondria: Emerging Consequential in Sickle Cell Disease. *J Clin Med* 12(3): 765.
 15. Zhu X, Oseghale AR, Nicole LH, Li B, Pace BS (2019) Mechanisms of NRF2 Activation to Mediate Fetal Hemoglobin Induction and Protection against Oxidative Stress in Sickle Cell Disease. *Exp Biol Med* 244(2): 171-182.
 16. Forrester SJ, Kikuchi DS, Hernandez MS, Xu Q, Griendling KK (2018) Reactive Oxygen Species in Metabolic and Inflammatory Signaling. *Circ Res* 122(6): 877-902.
 17. Su LJ, Zhang JH, Gomez H, Murugan R, Hong X, et al. (2019) Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis. *Oxid Med Cell Longev* 2019: 5080843.
 18. Lepetos P, Papavassiliou KA, Papavassiliou AG (2019) Redox and NF- κ B Signaling in Osteoarthritis. *Free Radic Biol Med* 132: 90-100.
 19. Kowalczyk P, Sulejczak D, Kleczkowska P, Bukowska-Osko I, Kucia M, et al. (2021) Mitochondrial Oxidative Stress-A Causative Factor and Therapeutic Target in many Diseases. *Int J Mol Sci* 22(24): 13384.
 20. Singh A, Kukreti R, Saso L, Kukreti S (2019) Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. *Molecules* 24(8): 1583.
 21. Yang M, Silverstein RL (2019) CD36 Signaling in Vascular Redox Stress. *Free Radic Biol Med* 136: 159-171.
 22. Zhang Y, Unnikrishnan A, Deepa SS, Liu Y, Li Y, et al. (2017) A New Role for Oxidative Stress in Aging: The Accelerated Aging Phenotype in Sod1-/- Mice is Correlated to Increased Cellular Senescence. *Redox Biol* 11: 30-37.
 23. Plascencia-Villa G, Perry G (2021) Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis. *Antioxid Redox Signal* 34(8): 591-610.
 24. Pisoschi AM, Pop A, Iordache F, Stanca L, Predoi G, et al. (2021) Oxidative Stress Mitigation by Antioxidants-An Overview on their Chemistry and Influences on Health Status. *Eur J Med Chem* 209: 112891.
 25. Zhao H, Eguchi S, Alam A, Ma D (2017) The Role of Nuclear Factor-Erythroid 2 Related Factor 2 (Nrf-2) in the Protection against Lung Injury. *American Journal of Physiology-Lung Cellular and Molecular Physiology* 312(2): L155-L162.
 26. De Oliveira MR, Nabavi SF, Manayi A, Daglia M, Hajheydari Z, et al. (2016) Resveratrol and The Mitochondria: From Triggering the Intrinsic Apoptotic Pathway to Inducing Mitochondrial Biogenesis, A Mechanistic View. *Biochimica et Biophysica Acta (BBA)-General Subjects* 1860(4): 727-745.
 27. Charlton A, Garzarella J, Jandeleit-Dahm KA, Jha JC (2020) Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes. *Biology* 10(1): 18.
 28. Policastro LL, Ibanez IL, Notcovich C, Duran HA, Podhajcer OL (2013) The Tumor Microenvironment: Characterization, Redox Considerations, and Novel Approaches for Reactive Oxygen Species-Targeted Gene Therapy. *Antioxid Redox Signal* 19(8): 854-895.
 29. Vaiserman A, Koliada A, Zayachkivska A, Lushchak O (2020) Nanodelivery of Natural Antioxidants: An Anti-Aging Perspective. *Front Bioeng Biotechnol* 7: 447.
 30. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO (2015) Sickle Cell Anaemia: A Review. *Sch J App Med Sci* 3(6B): 2244-2252.
 31. Obeagu EI (2020) Erythropoietin in Sickle Cell Anaemia: A Review. *International Journal of Research Studies in Medical and Health Sciences* 5(2): 22-28.
 32. Obeagu EI (2018) Sickle Cell Anaemia: Haemolysis and Anemia. *Int J Curr Res Chem Pharm Sci* 5(10): 20-21.
 33. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, et al. (2022) An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia

- Crisis. *J Biomed Sci* 11(10): 84.
34. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC (2023) Sick Cell Anaemia: A Gestational Enigma. *European Journal of Biomedical and Pharmaceutical Sciences* 10((9): 72-75.
 35. Obeagu EI (2018) An Update on Micro RNA in Sick Cell Disease. *Int J Adv Res Biol Sci* 5(10): 157-158.
 36. Obeagu EI, Babar Q (2021) Covid-19 and Sick Cell Anemia: Susceptibility and Severity. *Journal of Clinical and Laboratory Research* 4(1): 56.
 37. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP (2023) Men's Essential Roles in the Management of Sick Cell Anemia. *Newport International Journal of Scientific and Experimental Sciences* 4(2): 20-29.
 38. Obeagu EI (2023) Depression in Sick Cell Anemia: An Overlooked Battle. *Int J Curr Res Chem Pharm Sci* 10(10).
 39. Obeagu EI, Obeagu GU (2023) Evaluation of Hematological Parameters of Sick Cell Anemia Patients with Osteomyelitis in a Tertiary Hospital in Enugu, Nigeria. *Journal of Clinical and Laboratory Research* 6(1): 94.
 40. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU, et al. (2023) Hyperthyroidism in Sick Cell Anaemia. *IDOSR Journal of Applied Sciences* 8(2): 52-57.
 41. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC (2023) Nosocomial Infections in Sick Cell Anemia Patients: Prevention through Multi-Disciplinary Approach: A Review. *Medicine* 102(48): e36462.
 42. Njar VE, Ogunnaya FU, Obeagu EI (2023) Knowledge and Prevalence of the Sick Cell Trait among Undergraduate Students of the University of Calabar. *Prevalence* 5(100): 0-5.
 43. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B (2018) Expression of Micro RNA 144 in Sick Cell Disease. *Int J Curr Res Med Sci* 4(3): 26-32.
 44. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU (2023) Anaemia in Children under Five Years: African Perspectives. *Int J Curr Res Biol Med* 8(1): 1-7.
 45. Obeagu EI (2018) Sick Cell Anaemia: Historical Perspective, Pathophysiology and Clinical Manifestations. *Int J Curr Res Chem Pharm Sci* 5(11): 13-15.
 46. Obeagu EI, Obeagu GU (2023) Sick Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences* 6(2): 10-13.
 47. Obeagu EI, Mohamad AH (2023) An Update on Iron Deficiency Anaemia among Children with Congenital Heart Disease. *Int J Curr Res Chem Pharm Sci* 10(4): 45-48.
 48. Edward U, Osuorji VC, Nnodim J, Obeagu EI (2022) Evaluation of Trace Elements in Sick Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. *Madonna University Journal of Medicine and Health Sciences* 2(1): 218-234.
 49. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, et al. () Assessment of Factors Precipitating Sick Cell Crises among Under 5-Years Children Attending Sick Cell Clinic of Murtala Muhammad Specialist Hospital, Kano. *J Bio Innov* 12(2): 297-302.
 50. Obeagu EI (2018) Vaso-Occlusion and Adhesion Molecules in Sick Cells Disease. *Int J Curr Res Med Sci* 4(11): 33-35.
 51. Ifeanyi OE, Stella EI, Favour AA (2018) Antioxidants in the Management of Sick Cell Anaemia. *Int J Hematol Blo Dis* 3(2): 1-2.
 52. Buhari HA, Ahmad AS, Obeagu EI (2023) Current Advances in the Diagnosis and Treatment of Sick Cell Anaemia. *Newport International Journal of Biological and Applied Sciences (NIJBAS)* 4(1): 1-10.
 53. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, et al. (2015) Hcpidin and Erythropoietin Level in Sick Cell Disease. *Journal of Advances in Medicine and Medical Research* 8(3): 261-265.
 54. Obeagu EI (2023) Burden of Chronic Osteomyelitis: Review of Associated Factors. *Madonna University Journal of Medicine and Health Sciences* 3(1): 1-6.
 55. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, et al. (2015) Antioxidant-Mediated Heinz Bodies Levels of Sick Erythrocytes under Drug-Induced Oxidative Stress. *European Journal of Biomedical and Pharmaceutical Sciences* 2(1): 502-507.
 56. Obeagu EI, Malot S, Obeagu GU, Ugwu OP (2023) HIV Resistance in Patients with Sick Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)* 3(2): 56-59.
 57. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO (2023) Sick Cell Anaemia: Current Burden in Africa. *International Journal of Innovative and Applied Research* 11(2): 12-14.
 58. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN (2014) Haematological Parameters among Sick Cell

Anemia Patients' State and Haemoglobin Genotype AA Individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *Int J Curr Microbiol App Sci* 3(3): 1000-1005.

59. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU (2023) Obstetrics Characteristics that Effect the Newborn Outcomes. *Int J Adv Res Biol Sci* 10(3): 134-143.
60. Obeagu EI, Opoku D, Obeagu GU (2023) Burden of Nutritional Anaemia in Africa: A Review. *Int J Adv Res Biol Sci* 10(2): 160-163.
61. Ifeanyi E (2015) Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection

in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *Paripex - Indian Journal of Research* 4(6): 258-259

62. Ifeanyi OE, Stanley MC, Nwakaego OB (2014) Comparative Analysis of Some Haematological Parameters in Sickle Cell Patients in Steady and Crisis State at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *Int J Curr Microbiol App Sci* 3(3): 1046-1050.
63. Ifeanyi EO, Uzoma GO (2020) Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. *J Clin Med Res* 2(2): 1-4.